OPTRUMA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain, Tunisia.

Active ingredients

The drug OPTRUMA contains one active pharmaceutical ingredient (API):

1	Raloxifene UNII 4F86W47BR6 - RALOXIFENE HYDROCHLORIDE
	As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.
	Read more about Raloxifene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OPTRUMA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03XC01	Raloxifene	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system → G03XC Selective estrogen receptor modulators
Discover more medicines within G03XC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1197761, 1197772, 1197783, 1197794
ES	Centro de información online de medicamentos de la AEMPS	98074002
FR	Base de données publique des médicaments	69445593
IT	Agenzia del Farmaco	034154017, 034154029
LT	Valstybinė vaistų kontrolės tarnyba	1030349, 1030350, 1030351, 1030352
PL	Rejestru Produktów Leczniczych	100125603
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51630001, W51630002, W51630003, W51630004
TN	Direction de la Pharmacie et du Médicament	4323012